CG
CGNSF.US Cognetivity Neurosciences Ltd
- Market cap
- USD 8.96K
- P/E
- -
- P/B
- 189.01x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Oct 2023.
Is CGNSF.US undervalued?
Graham numberThe Graham number of Cognetivity Neurosciences Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cognetivity Neurosciences Ltd fundamental analysis
No fundamental analysis for Cognetivity Neurosciences Ltd yet.
Cognetivity Neurosciences Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cognetivity Neurosciences Ltd
Cognetivity Neurosciences Ltd. operates as a technology company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia; and OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Va…
Full company profileCognetivity Neurosciences Ltd financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Oct 31, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cognetivity Neurosciences Ltd annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 45.4K | 71.5K |
| Gross Profit | -11.0K | -240.00 | -1.43K | -3.94K | -9.29K | -11.4K | -24.5K | -2.13M | -588K |
| Operating Income | -82.1K | -495K | -1.49M | -4.21M | -2.60M | -2.39M | -13.0M | -6.29M | -3.88M |
| EBITDA | -0.34 | -494K | -1.49M | -4.21M | -2.60M | -2.39M | -13.0M | -6.38M | -3.23M |
| Net Income | -68.6K | -459K | -1.50M | -4.19M | -2.65M | -1.93M | -13.1M | -7.43M | -8.10M |
| EPS | 0.00 | -0.01 | -0.04 | -0.10 | -0.06 | -0.03 | -0.18 | -0.09 | -0.09 |
| Balance Sheet | |||||||||
| Total Assets | 546.62 | 68.5K | 3.75M | 716K | 748K | 1.83M | 2.00M | 2.83M | 487K |
| Total Liabilities | 123K | 168K | 366K | 237K | 1.01M | 965K | 7.68M | 12.7M | 15.7M |
| Shareholders' Equity | -123K | -99.4K | 3.39M | 479K | -263K | 863K | -5.68M | -9.89M | -15.2M |
| Cash & Short-term Investments | 187.53 | 32.2K | 3.61M | 379K | 578K | 1.36M | 1.38M | 2.24M | 16.6K |
| Total Debt | - | - | - | - | 307K | 314K | 1.29M | 1.29M | 2.74M |
| Cash Flow | |||||||||
| Operating Cash Flow | 187.53 | -326K | -860K | -3.49M | -1.86M | -1.96M | -3.21M | -5.94M | -2.90M |
| Capital Expenditure | 3.26K | 3.26K | 8.58K | 21.1K | 21.8K | 50.1K | 100K | 69.7K | 37.9K |
| Free Cash Flow | 187.53 | -329K | -868K | -3.51M | -1.88M | -2.01M | -3.31M | -6.01M | -2.94M |
| Ratios | |||||||||
| ROE | - | - | -44.1% | -874.5% | - | -223.4% | - | - | - |
| ROA | -12,558.7% | -670.1% | -39.8% | -585.3% | -353.6% | -105.5% | -654.8% | -262.7% | -1,665.6% |
| Net Profit Margin | - | - | - | - | - | - | - | -16,386.3% | -11,339.7% |
| Debt to Equity | - | - | - | - | - | 0.36x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cognetivity Neurosciences Ltd dividends
Cognetivity Neurosciences Ltd has not paid dividends in the last 8 fiscal years.
Who owns Cognetivity Neurosciences Ltd
- Insiders 13.50%
- Institutions 0.00%
- Public & others 86.50%
- Shares outstanding 89.6M
- Free float 82.2M
Cognetivity Neurosciences Ltd company profile
- Company name
- Cognetivity Neurosciences Ltd
- Ticker
- CGNSF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Technology
- Fiscal year end
- January
- Address
- 1055 West Hastings Street, Vancouver, BC, Canada, V6E 2E9
- Phone
- 604 688 9588
- Website
- cognetivity.com
About Cognetivity Neurosciences Ltd
Cognetivity Neurosciences Ltd. operates as a technology company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia; and OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Cognetivity Neurosciences Ltd management
3- Dr. Sina HabibiCo-Founder, CEO & Director
- Dr. Seyed-Mahdi Khaligh-RazaviCo-Founder & CIO
- Dr. Thomas Roger Sawyer M.B.A., Ph.D.CFO, Company Secretary & Director · born 1970